A standard model of Alzheimer’s disease?

ABSTRACT The recent Research Framework proposed by the US National Institute on Aging and the Alzheimer’s Association (NIA-AA) recommends that Alzheimer’s disease be defined by its specific biology rather than by non-specific neurodegenerative and syndromal features. By affirming markers of abnormal Aβ and tau proteins as the essential pathobiological signature of Alzheimer’s disease, the Framework tacitly reinforces the amyloid (Aβ) cascade as the leading theory of Alzheimer pathogenesis. In light of recent evidence that the cascade is driven by the misfolding and templated aggregation of Aβ and tau, we believe that an empirically grounded Standard Model of Alzheimer’s pathogenesis is within reach. A Standard Model can clarify and consolidate existing information, contextualize risk factors and the complex disease phenotype, identify testable hypotheses for future research, and pave the most direct path to effective prevention and treatment.

[1]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[2]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[3]  I. Dewachter,et al.  Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism , 2014, Molecular Neurodegeneration.

[4]  S. Lesné.  Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue. , 2014, Swiss medical weekly.

[5]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[6]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[7]  U. Sengupta,et al.  Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases , 2016, Journal of Alzheimer's disease : JAD.

[8]  S. Linse,et al.  Secondary nucleation in amyloid formation. , 2018, Chemical communications.

[9]  K. Jellinger,et al.  Amyloid and tau: neither chicken nor egg but two partners in crime! , 2013, Acta Neuropathologica.

[10]  J. Collinge,et al.  Prion propagation and toxicity in vivo occur in two distinct mechanistic phases , 2011, Nature.

[11]  M. Diamond,et al.  The prion model for progression and diversity of neurodegenerative diseases , 2017, The Lancet Neurology.

[12]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[13]  D. Teplow,et al.  Amyloid β-protein oligomers and Alzheimer’s disease , 2013, Alzheimer's Research & Therapy.

[14]  L. Thomas.  Biomedical science and human health: the long-range prospect. , 1977, Daedalus.

[15]  H. Braak,et al.  Reply: the early pathological process in sporadic Alzheimer’s disease , 2013, Acta Neuropathologica.

[16]  Nathan D. Price,et al.  Summary of the 11th International Conference on Human Herpesviruses‐6A, ‐6B, and ‐7 , 2018, Neuron.

[17]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[18]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[19]  S. Prusiner.  Biology and genetics of prions causing neurodegeneration. , 2013, Annual review of genetics.

[20]  M. Frosch,et al.  Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain , 2018, Acta Neuropathologica.

[21]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[22]  J. Hardy,et al.  Amyloid or tau: the chicken or the egg? , 2013, Acta Neuropathologica.

[23]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[24]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[25]  Chengjie Xiong,et al.  The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.

[26]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[27]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[28]  L. Walker.  Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. , 2016, Annual review of genetics.

[29]  J. Butterworth,et al.  The Standard Model: how far can it go and how can we tell? , 2016, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[30]  D. Henze,et al.  The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. , 2006, Current topics in medicinal chemistry.

[31]  D. Holtzman,et al.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.

[32]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.